Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act Of
1934
Date of
Report (Date of earliest event reported): November 1,
2016
Palatin Technologies, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-15543
|
95-4078884
|
|
(State
or other jurisdiction
|
(Commission
|
(IRS
employer
|
|
of
incorporation)
|
File
Number)
|
identification
number)
|
|
4B Cedar Brook Drive, Cranbury, NJ
|
08512
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (609) 495-2200
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On
November 1, 2016, we issued a press release announcing positive
top-line results in our Phase 3 clinical trial program of
bremelanotide as an on-demand treatment for premenopausal women
diagnosed with hypoactive sexual desire disorder, and announcing a
teleconference and audio webcast to be held November 2 at 9:00 a.m.
Eastern Time, which will include a discussion of top-line results
of the Phase 3 bremelanotide efficacy trials. Bremelanotide 1.75 mg
met the pre-specified co-primary efficacy endpoints of improvement
in desire and decrease in distress associated with low sexual
desire as measured using validated patient-report outcome
instruments.
We have
attached a copy of the press release as exhibit 99.1 to this
report, which press release is incorporated by reference
herein.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits:
Press Release dated
November 1, 2016
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
PALATIN
TECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
November 1, 2016
|
By:
|
/s/
Stephen T. Wills
|
|
|
|
|
Stephen
T. Wills, CPA, MST
Executive
Vice President, Chief Financial Officer and Chief Operating
Officer
|
|
EXHIBIT INDEX
Press Release dated
November 1, 2016